目的 探讨复方玄驹胶囊联合左氧氟沙星和前列康片治疗Ⅲ型前列腺炎的临床疗效.方法 选取2012 年1 月-2015年1 月北京市通州区新华医院收治的Ⅲ型前列腺炎患者156 例,随机分为对照组和治疗组,每组78 例.对照组口服左氧氟沙星片5 片/次,1 次/d,口服前列康片3 片/次,3 次/d.治疗组在对照组基础上口服复方玄驹胶囊3 粒/次,3 次/d.两组均连续治疗6 周.观察两组的临床疗效,同时比较两组NIH-CPSI 评分和前列腺液检查的变化情况.结果 治疗后,对照组和治疗组总有效率分别为51.28%、71.79%,两组比较差异具有统计学意义(P< 0.05).治疗后两组NIH-CPSI 总分、疼痛、排尿、生活质量得分均较治疗前显著降低,同组治疗前后差异有统计学意义(P< 0.05),且治疗组显著低于对照组,两组比较差异有统计学意义(P< 0.05).治疗后,两组精液中白细胞介素-6(IL-6)、白细胞水平均显著降低,同组治疗前后差异有统计学意义(P< 0.05),且治疗组显著低于对照组,两组比较差异有统计学意义(P< 0.05).结论 复方玄驹胶囊联合左氧氟沙星和前列康片治疗Ⅲ型前列腺炎疗效显著,可显著降低NIH-CPSI 评分,具有一定的临床推广应用价值.

Objective To investigate the curative effect of Compound Xuanju Capsule combined with levofloxacin and Qianliekang Tablets in treatment of type Ⅲ prostatitis. Methods Patients (156 cases) with type Ⅲ prostatitis in Beijing Tongzhou Xinhua Hospital from January 2012 to January 2015 were randomly divided into control and treatment groups. Each group had 78 cases. Patients in control group were po administered with Levofloxacin Tablets, 5 tablets/time, once daily, and they were po administered with Qianliekang Tablets, 3 tablets/time, three times daily. Patients in treatment group were po administered with Compound Xuanju Capsule on the basis of the control group, 3 grains/time, three times daily. Two groups were treated for 6 weeks. After treatment, the efficacy was evaluated, and NIH-CPSI score and examination of prostatic fluid in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 51.28% and 71.79%, respectively, and there were differences between two groups (P < 0.05). After treatment, NIH-CPSI total score, scores of pain, micturition, and life quality in two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment were significantly lower than those in the control group, with significant differences between two groups (P < 0.05). After treatment, IL-6 and white blood cell in the semen of two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment were significantly lower than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Compound Xuanju Capsule combined with levofloxacin and Qianliekang Tablets has curative effec in treatment of type Ⅲ prostatitis, and can significantly reduce the NIH-CPSI score, which has a certain clinical application value.